Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 3/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 7/20 | 0.41 |
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11850140 | 0.91 | CDC25B (0.46) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL11846780 | 0.89 | CDC25B (0.41) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL11850356 | 0.88 | WDR5 (0.44) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL11846678 | 0.88 | GAA (0.56) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL11841970 | 0.87 | AKR1C3 (0.45) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL11842798 | 0.87 | NPSR1 (0.44) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL11846740 | 0.86 | PTK2B (0.56) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL11780958 | 0.85 | CA1 (0.55) | KDM4EALDH1A1GAAMAPTCA2 | |
| SCHEMBL11850451 | 0.84 | PKM (0.48) | KDM4EALDH1A1GAAMAPTTHRB | |
| SCHEMBL11849822 | 0.84 | AKR1C3 (0.52) | KDM4EALDH1A1GAAMAPTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010085352-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-3985777-A | Sulphamyl-benzoic acid derivatives | LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB (DK) | 1976-10-12 | — | — | US | disclosed |
| US-3933906-A | DIURETIC | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
| US-3933906-A | DIURETIC | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
| US-3927218-A | 3,4-Bisamino-5-sulfamoylbenzoic acids useful as diuretic agents | CIBA GEIGY CORP | 1975-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | KDM4E 2228/4885ALDH1A1 889/4885GAA 848/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | KDM4E 2764/4885ALDH1A1 625/4885GAA 887/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | KDM4E 3528/4885ALDH1A1 1389/4885GAA 2397/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | KDM4E 3717/4885ALDH1A1 845/4885GAA 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.